GALT Galectin Therapeutics, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

Settings

GALT [NASD]

Galectin Therapeutics, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-0.34	Insider Own	14.10%	Shs Outstand	57.04M	Perf Week	-4.40%
Market Cap	151.22M	Forward P/E	-	EPS next Y	-0.68	Insider Trans	0.06%	Shs Float	40.55M	Perf Month	-5.09%
Income	-17.80M	PEG	-	EPS next Q	-0.14	Inst Own	17.60%	Short Float	13.10%	Perf Quarter	-2.97%
Sales	-	P/S	-	EPS this Y	-1.20%	Inst Trans	0.28%	Short Ratio	17.39	Perf Half Y	29.85%
Book/sh	0.61	P/B	4.28	EPS next Y	-47.80%	ROA	-38.50%	Target Price	-	Perf Year	-34.09%
Cash/sh	0.70	P/C	3.71	EPS next 5Y	-	ROE	-42.80%	52W Range	1.50 - 4.50	Perf YTD	-8.74%
Dividend	-	P/FCF	-	EPS past 5Y	13.00%	ROI	-	52W High	-41.33%	Beta	2.34
Dividend %	-	Quick Ratio	9.60	Sales past 5Y	-	Gross Margin	-	52W Low	76.00%	ATR	0.20
Employees	7	Current Ratio	9.60	Sales Q/Q	-	Oper. Margin	-	RSI (14)	45.69	Volatility	4.16% 8.65%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	-77.80%	Profit Margin	-	Rel Volume	0.41	Prev Close	2.61
Shortable	Yes	LT Debt/Eq	0.00	Earnings	-	Payout	-	Avg Volume	305.50K	Price	2.64
Recom	2.00	SMA20	-3.74%	SMA50	-5.59%	SMA200	2.06%	Volume	93,751	Change	1.15%

Aug-13-20

Reiterated

H.C. Wainwright

Buy

$9 → $12

Feb-13-19

Initiated

B. Riley FBR

Buy

$11

Dec-07-17

Reiterated

H.C. Wainwright

Buy

$6 → $10

Nov-28-17

Reiterated

H.C. Wainwright

Buy

$3.50 → $6

Oct-19-17

Initiated

ROTH Capital

Buy

Mar-30-17

Upgrade

H.C. Wainwright

Neutral → Buy

$3.50

Oct-03-16

Downgrade

FBR & Co.

Outperform → Mkt Perform

$12 → $2

Sep-29-16

Downgrade

H.C. Wainwright

Buy → Neutral

$1.50

Sep-28-16

Downgrade

ROTH Capital

Buy → Sell

Mar-28-16

Resumed

H.C. Wainwright

Buy

Sep-21-15

Initiated

H.C. Wainwright

Buy

Aug-01-14

Downgrade

Aegis Capital

Buy → Hold

Jul-30-14

Reiterated

MLV & Co

Buy

$27 → $16

Jul-29-14

Reiterated

MLV & Co

Buy

$27 → $15

Apr-02-14

Reiterated

MLV & Co

Buy

$20 → $27

Feb-10-14

Reiterated

Aegis Capital

Buy

$16 → $32

Jan-09-14

Reiterated

Aegis Capital

Buy

$10 → $16

Dec-03-13

Initiated

MLV & Co

Buy

$20

Aug-19-13

Reiterated

Aegis Capital

Buy

$7 → $10

Oct-12-20 08:11AM	New Strong Sell Stocks for October 12th Zacks
Oct-06-20 03:30PM	These 2 Penny Stocks Could Quadruple (Or More), Says H.C. Wainwright TipRanks
Sep-29-20 12:00PM	Galectin Therapeutics Investor Conference Call and Webinar Taking Place Today GlobeNewswire -9.34%
08:52AM	Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options Zacks
Sep-22-20 08:04AM	Galectin Therapeutics Announces Investor Conference Call and Webinar on September 29, 2020 GlobeNewswire
Sep-10-20 08:00AM	Galectin Therapeutics Inc. to Present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020 GlobeNewswire
Sep-09-20 11:46AM	Insider Buys Galectin Therapeutics Stock Benzinga +6.79%
Sep-02-20 08:00AM	Galectin Therapeutics Appoints Joel Lewis as Chief Executive Officer GlobeNewswire
Aug-10-20 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2020, and Provides Business Update GlobeNewswire
Aug-03-20 12:48PM	Is Galectin Therapeutics, Inc.'s (NASDAQ:GALT) Shareholder Ownership Skewed Towards Insiders? Simply Wall St.
Jun-30-20 09:05AM	UPDATE -- Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis GlobeNewswire
08:00AM	Galectin Therapeutics Announces Commencement of Patient Enrollment of the Adaptively-Designed Phase 2b/3 Trial of Belapectin in NASH Cirrhosis GlobeNewswire
Jun-04-20 09:48PM	Hedge Funds Are Souring On Galectin Therapeutics Inc. (GALT) Insider Monkey
May-22-20 08:17AM	Galectin Therapeutics' Shares March Higher, Can It Continue? Zacks +8.25%
May-11-20 08:00AM	Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2020, and Provides Business Update GlobeNewswire
May-04-20 08:37AM	Companies Like Galectin Therapeutics (NASDAQ:GALT) Are In A Position To Invest In Growth Simply Wall St. +8.52%
Apr-30-20 09:00AM	Galectin Therapeutics Submits Seamless Adaptively-Designed Phase 2b/3 NASH-RX Protocol in NASH Cirrhosis GlobeNewswire -8.97%
Apr-02-20 08:04AM	Galectin Therapeutics Update on the Impact of COVID-19 GlobeNewswire -7.26%
Mar-16-20 08:00AM	Galectin Therapeutics Reports Fiscal 2019 Financial Results and Provides Business Update GlobeNewswire -17.41%
Feb-20-20 08:00AM	Galectin Therapeutics Appoints Seasoned Biopharmaceutical Executive Pol F. Boudes, M.D. as Chief Medical Officer GlobeNewswire +6.32%
Feb-05-20 04:11PM	13 Key NASH Drug Candidates To Watch For In A Potential $30-Billion Market Benzinga
Feb-04-20 08:04AM	Are Insiders Buying Galectin Therapeutics, Inc. (NASDAQ:GALT) Stock? Simply Wall St.
08:00AM	Galectin Therapeutics President and CEO Dr. Harold Shlevin to Present at the 3rd Global NASH Congress 2020 GlobeNewswire
Dec-20-19 06:38PM	Is Galectin Therapeutics Inc. (GALT) Going to Burn These Hedge Funds? Insider Monkey
Dec-09-19 08:00AM	Galectin Therapeutics Phase 2 NASH Cirrhosis Clinical Trial Results on Belapectin (GR-MD-02) Published in Gastroenterology GlobeNewswire
Dec-05-19 12:06PM	Galectin Therapeutics Plans Adaptively Designed Phase 3 NASH-RX Clinical Trial in NASH Cirrhosis GlobeNewswire
Nov-26-19 08:00AM	Galectin Therapeutics to Webcast Corporate Update on December 4, 2019, after Annual Meeting of Stockholders GlobeNewswire
Nov-18-19 04:10PM	Galectin Therapeutics to Present at Anti-Fibrotic Drug Development (AFDD) Summit GlobeNewswire
Nov-12-19 08:00AM	Galectin Therapeutics Reports Q3 2019 Financial Results GlobeNewswire -16.90%
Nov-11-19 09:47AM	Galectin Therapeutics Reaches Agreement with Siemens Healthineers to Collaborate on NASH and Liver Fibrosis GlobeNewswire +8.82%
Nov-05-19 08:00AM	Additional Ad Hoc Analysis of ELF Data from Galectin Therapeutics NASH-CX Phase 2 Clinical Trial to be Highlighted in Poster Presentation at the 2019 AASLD Liver Meeting GlobeNewswire
Oct-28-19 08:39AM	We're Not Worried About Galectin Therapeutics's (NASDAQ:GALT) Cash Burn Simply Wall St.
Sep-17-19 08:00AM	Galectin Therapeutics, Inc. and Providence Cancer Institute Receive Patent on the Use of Belapectin (GR-MD-02) in Cancer Immunotherapy GlobeNewswire
Sep-11-19 10:13AM	Small Drug Stock Outlook: Innovation Holds the Key to Growth Zacks +5.57%
Aug-27-19 03:21PM	Need To Know: Galectin Therapeutics, Inc. (NASDAQ:GALT) Insiders Have Been Buying Shares Simply Wall St. -5.66%
10:21AM	New Strong Buy Stocks for August 27th Zacks
09:00AM	FibroGen (FGEN) Catches Eye: Stock Jumps 7.4% Zacks
Aug-09-19 08:00AM	Galectin Therapeutics Reports Q2 2019 Financial Results and Provides Business Update GlobeNewswire
Aug-07-19 11:20AM	Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View Zacks
11:15AM	Endo (ENDP) Q2 Earnings & Revenues Beat Estimates, Down Y/Y Zacks
Aug-06-19 10:51AM	Zoetis (ZTS) Beats on Earnings in Q2, Lifts 2019 Guidance Zacks
Aug-05-19 08:05AM	Galectin Therapeutics Submits Phase 3 NASH-RX Protocol in Nash Cirrhosis to FDA GlobeNewswire
May-28-19 09:05AM	Galectin Therapeutics Raises $44.5 Million in Rights Offering and $2.5 Million from Warrant Exercise GlobeNewswire
May-27-19 08:44AM	What Type Of Shareholder Owns Galectin Therapeutics, Inc.'s (NASDAQ:GALT)? Simply Wall St.
May-23-19 05:30PM	Galectin Therapeutics Reports Alternate Price of Common Stock in Rights Offering GlobeNewswire -5.65%
May-10-19 08:05AM	Galectin Therapeutics Releases Richard E. Uihleins Open Letter to Stockholders Dated May 10, 2019 GlobeNewswire
08:00AM	Galectin Therapeutics Reports Q1 2019 Financial Results and Provides Business Update GlobeNewswire
Apr-15-19 08:00AM	Galectin Therapeutics Inc. Announces Record Date, Subscription Pricing, and Expiration Date for Rights Offering and Effectiveness of its Registration Statement GlobeNewswire
Apr-02-19 08:00AM	Galectin Therapeutics to Present at the 2019 H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Mar-22-19 10:19AM	Providence Cancer Institute to Present Findings on GR-MD-02 at the 2019 Keystone Symposia on Molecular and Cellular Biology GlobeNewswire -6.56%
Mar-06-19 11:34AM	Investors Who Bought Galectin Therapeutics Shares Three Years Ago Are Now Up 248% Simply Wall St.
08:03AM	Galectin Therapeutics Releases Richard E. Uihleins Open Letter to Stockholders GlobeNewswire
08:02AM	Galectin Therapeutics Files Registration Statement for Stockholder Rights Offering of Common Stock and Warrants GlobeNewswire
08:00AM	Galectin Therapeutics Reports Fiscal 2018 Financial Results and Provides Business Update GlobeNewswire
Feb-26-19 07:25AM	Market Trends Toward New Normal in Infinera, Alliant Energy, Galectin Therapeutics, DexCom, Cutera, and Care Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-25-19 08:00AM	Galectin Therapeutics to Present at Berenberg NASH Day in New York GlobeNewswire
Feb-13-19 03:36PM	Conatus (CNAT) Completes Enrollment in Phase II NASH Study Zacks
09:53AM	Ascendis Pharma Files IND for Hypoparathyroidism Candidate Zacks
Feb-04-19 09:27AM	Alkermes Sinks as FDA Refuses to Approve Depression Drug Zacks
Feb-01-19 10:07AM	AVEO Oncology Plunges on Delay in Filing Fotivda NDA With FDA Zacks
Jan-30-19 09:30AM	Is Galectin Therapeutics (GALT) Stock Outpacing Its Medical Peers This Year? Zacks
Jan-15-19 08:00AM	Galectin Therapeutics Largest Institutional Shareholder Converts Existing Series B Preferred Stock Into Common Stock Streamlining Its Capital Structure GlobeNewswire
Dec-25-18 01:28PM	Did Galectin Therapeutics, Inc. (NASDAQ:GALT) Insiders Sell Shares? Simply Wall St.
Dec-20-18 08:30AM	Galectin Therapeutics Announces Extension of $10 Million Line Credit GlobeNewswire -13.53%
Nov-27-18 08:15AM	New Research: Key Drivers of Growth for Martin Midstream Partners, Galectin Therapeutics, Mountain Province Diamonds, MINDBODY, Pareteum, and Pieris Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire -5.37%
Nov-19-18 09:19AM	Galectin Therapeutics to Present at the 2nd Annual Anti-Fibrotic Drug Development Summit GlobeNewswire
Nov-13-18 08:00AM	Galectin Therapeutics Reports 2018 Third Quarter Financial Results and Provides Business Update GlobeNewswire
Nov-05-18 08:37AM	Implied Volatility Surging for Galectin Therapeutics (GALT) Stock Options Zacks +8.09%
08:00AM	Data Collected by Exalenz Bioscience in Galectin Therapeutics Phase 2 NASH-CX Trial of GR-MD-02 to Be Presented at AASLD Annual Meeting GlobeNewswire
Oct-15-18 10:22AM	Galectin Therapeutics to Participate in The ROTH Capital Battle of the NASH Thrones Investment Conference GlobeNewswire
08:00AM	Galectin Therapeutics to Present at The ROTH Capital Battle of the NASH Thrones Investment Conference GlobeNewswire
Oct-11-18 07:30AM	Market Trends Toward New Normal in Altra Industrial Motion, IDEXX Laboratories, BioTelemetry, Galectin Therapeutics, NETGEAR, and Merck & Co. Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Sep-26-18 03:21PM	5 Biotech Stocks to Play the Sectors Next Big Trend: NASH InvestorPlace
Sep-21-18 10:43AM	Galectin's GR-MD-02 Positive in Phase Ib Study With Keytruda Zacks -5.77%
08:00AM	Today's Research Reports on Trending Tickers: MiMedx Group and Galectin Therapeutics ACCESSWIRE
Sep-20-18 08:25AM	Galectin stock lifts 15% premarket on early cancer combination trial results MarketWatch +14.55%
08:00AM	Galectin Therapeutics, Inc. Announces Positive Preliminary Results from Phase 1b Clinical Trial of GR-MD-02 and KEYTRUDA® in Advanced Melanoma and Expansion of the Trial GlobeNewswire
Sep-18-18 08:53AM	Is the Options Market Predicting a Spike in Galectin Therapeutics (GALT) Stock? Zacks
Aug-31-18 02:46PM	Penny Stocks to Buy Using Technical Analysis for September 2018 Investopedia +10.41%
Aug-21-18 11:27AM	3 Marijuana Stocks & Biotech Stocks Capitalizing on Industry Momentum ACCESSWIRE +5.39%
Aug-20-18 08:42AM	Are Options Traders Betting on a Big Move in Galectin Therapeutics (GALT) Stock? Zacks +14.99%
Aug-14-18 08:00AM	Galectin Therapeutics Reports 2018 Second Quarter Financial Results and Provides Business Update GlobeNewswire
Aug-03-18 07:30AM	Market Trends Toward New Normal in Conn's, Herman Miller, TrueBlue, Brandywine Realty Trust, Tenneco, and Galectin Therapeutics Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Jul-26-18 08:57AM	3 Stocks That Could Double Your Money Motley Fool
Jul-11-18 07:45AM	Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks ACCESSWIRE
Jun-27-18 12:56PM	Why Galectin Therapeutics Stock Bolted Higher Today Motley Fool +6.40%
08:00AM	Galectin Therapeutics Receives Patent for GR-MD-02 Patent for Method and Treatment of Pulmonary Fibrosis GlobeNewswire
Jun-26-18 08:55AM	Is the Options Market Predicting a Spike in Galectin Therapeutics (GALT) Stock? Zacks -10.33%
Jun-22-18 10:40AM	Company Profile for Galectin Therapeutics Inc. Business Wire
Jun-17-18 04:17PM	2 Clinical-Stage Biotech Stocks That Could Soar Next Week Motley Fool
10:37AM	Market Sentiment Around Loss-Making Galectin Therapeutics Inc (NASDAQ:GALT) Simply Wall St.
Jun-16-18 07:18AM	3 Biotech Stocks That Soared This Week: Are They Buys? Motley Fool
Jun-15-18 08:07AM	3 NASH Stocks That Could Soar in the Second Half of 2018 Motley Fool +7.23%
Jun-14-18 09:23AM	NASH Space in Focus as Galmed (GLMD) Posts Positive Data Zacks
08:10AM	Todays Research Reports on Stocks to Watch: Flex Pharma and Galectin Therapeutics ACCESSWIRE
Jun-12-18 08:32AM	Galectin Therapeutics Inc. Announces New CEO GlobeNewswire +5.85%
Jun-04-18 09:00AM	Galectin Therapeutics Inc. Announces Richard E. Uihlein Elected Chairman of the Board GlobeNewswire
Jun-01-18 07:40AM	Free Stock Performance Review on Mallinckrodt and Three Additional Generic Drugs Stocks ACCESSWIRE
May-15-18 08:00AM	Todays Research Reports on Stocks to Watch: Tandem Diabetes Care and Galectin Therapeutics ACCESSWIRE
May-14-18 09:05AM	Galectin Therapeutics Proceeds to Phase 3 Development of GR-MD-02 for NASH Cirrhosis Following FDA Meeting GlobeNewswire +19.05%

Galectin Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing GR-MD-02 for the treatment of psoriasis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., is also involved in the research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics, Inc. was founded in 2000 and is based in Norcross, Georgia.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
10X Fund, L.P.	10% Owner	Oct 13	Sale	2.97	10,000	29,700	6,356,440	Oct 15 05:03 PM
Uihlein Richard E	Director	Sep 04	Buy	2.55	10,000	25,500	7,893,191	Sep 09 08:00 AM
FREEMAN KEVIN D	Director	Sep 04	Buy	2.57	5,000	12,848	25,000	Sep 09 08:00 AM
FREEMAN KEVIN D	Director	Mar 19	Buy	1.64	6,000	9,844	20,000	Mar 20 08:30 AM
Uihlein Richard E	Director	Feb 13	Option Exercise	3.05	65,513	200,003	7,883,191	Feb 14 08:01 AM
LEWIS JOEL	Director	Feb 09	Option Exercise	2.39	8,000	19,120	107,104	Feb 10 04:31 PM
10X Fund, L.P.	10% Owner	Jan 17	Sale	2.97	10,000	29,700	6,375,790	Jan 21 04:54 PM
FREEMAN KEVIN D	Director	Nov 15	Buy	3.36	3,000	10,076	14,000	Nov 18 10:01 AM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience